Notably, our study revealed that anlotinib treatment for over 48 h increased DNA‐PKcs expression in osteosarcoma cells, suggesting its potential relevance to the sensitivity of osteosarcoma to anlotinib. This evidence concerns the gene PRKDC and osteosarcoma.